POTENTIAL UNREALIZED CARDIOVASCULAR BENEFIT OF NOVEL DIABETES AGENTS IN THE VETERANS HEALTH ADMINISTRATION SYSTEM: INSIGHT FROM THE CLINICAL ASSESSMENT, REPORTING, AND TRACKING (CART) PROGRAM
Sign Up to like & getrecommendations! Published in 2020 at "Journal of the American College of Cardiology"
DOI: 10.1016/s0735-1097(20)32463-3
Abstract: Novel diabetes agents (glucagon-like-peptide-1 receptor agonists, GLP-1 RA and sodium-glucose cotransport-2 inhibitors, SGLT2i) reduced death and cardiovascular events in randomized trials, but uptake in clinical practice has lagged. We assessed the unrealized potential for reduction… read more here.
Keywords: potential unrealized; diabetes agents; unrealized cardiovascular; novel diabetes ... See more keywords
Metformin: evidence from preclinical and clinical studies for potential novel applications in cardiovascular disease
Sign Up to like & getrecommendations! Published in 2023 at "Expert Opinion on Investigational Drugs"
DOI: 10.1080/13543784.2023.2196010
Abstract: ABSTRACT Introduction For a long time, metformin has been the first-line treatment for glycemic control in type 2 diabetes; however, the results of recent cardiovascular outcome trials of sodium-glucose co-transporter 2 inhibitors and glucagon-like peptide… read more here.
Keywords: cardiovascular benefit; metformin evidence; preclinical clinical; clinical studies ... See more keywords
No cardiovascular benefit with evacetrapib – is this the end of the road for the ‘cetrapibs’?
Sign Up to like & getrecommendations! Published in 2017 at "Expert Opinion on Pharmacotherapy"
DOI: 10.1080/14656566.2017.1365838
Abstract: ABSTRACT Introduction: Increasing high-density lipoprotein(HDL) cholesterol levels predict improved cardiovascular outcomes. However, inhibiting cholesteryl ester transfer protein (CETP) to increase HDL cholesterol, with the ‘cetrapibs’ (torcetrapib and dalcetrapib), did not improve cardiovascular clinical outcomes. Despite… read more here.
Keywords: hdl cholesterol; cetrapibs; cardiovascular outcomes; cholesterol ... See more keywords
Cardiovascular benefit of egg consumption is most unlikely
Sign Up to like & getrecommendations! Published in 2018 at "Heart"
DOI: 10.1136/heartjnl-2018-313687
Abstract: To the Editor The conclusion of the recent report that egg consumption reduced cardiovascular risk1 is most unlikely to be valid. It has been clear for many years that dietary cholesterol increases coronary risk, and… read more here.
Keywords: benefit egg; consumption unlikely; egg; cardiovascular benefit ... See more keywords
Evaluation of the HbA1c Reduction Cut Point for a Nonglycemic Effect on Cardiovascular Benefit of Hypoglycemic Agents in Patients with Type 2 Diabetes Based on Endpoint Events
Sign Up to like & getrecommendations! Published in 2018 at "International Journal of Endocrinology"
DOI: 10.1155/2018/8457538
Abstract: Background Atherosclerotic cardiovascular disease (ASCVD) is a major cause of death among patients with diabetes but can be improved by certain hypoglycemic agents. However, adjudicating criteria on whether improvements are a glycemic or nonglycemic effect… read more here.
Keywords: reduction; effect; nonglycemic effect; hypoglycemic agents ... See more keywords
Multi-omics insights into potential mechanism of SGLT2 inhibitors cardiovascular benefit in diabetic cardiomyopathy
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Cardiovascular Medicine"
DOI: 10.3389/fcvm.2022.999254
Abstract: Background Metabolic and energy disorders are considered central to the etiology of diabetic cardiomyopathy (DCM). Sodium-glucose cotransporter-2 inhibitors (SGLT2i) can effectively reduce the risk of cardiovascular death and heart failure in patients with DCM. However,… read more here.
Keywords: cardiovascular benefit; sglt2i; mechanism; benefit ... See more keywords